• Blog
  • Age Related Macular Degeneration Drug Market Report

    Age Related Macular Degeneration Drug Market Report

    Age Related Macular Degeneration Drug Market Report
    Report code - SR1031 Delivery - 2 Weeks
    Get Free Sample |
    Play Audio
    Listen
    Global Age-Related Macular Degeneration Drug Market, Dynamics, Trends, and Market Analysis See more...

    Impact of COVID-19 on Age Related Macular Degeneration Drug Market

    Covid-19 has impacted the market dynamics, competition, and global...

    See more...

    Impact of COVID-19 on Age Related Macular Degeneration Drug Market

    Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.

    Note: The summary below might not have included insights on covid impact since we have large number of reports.

    Market Insights

    The Global Age-Related Macular Degeneration Drug Market is projected to grow from USD xx billion in 2020 to USD xx billion by 2026 at a CAGR of around x% during the forecast period.

    Figure: Global Age-Related Macular Degeneration Drug Market Size, 2020-2026 (USD Billion)

    Age-Related-Macular-Degeneration-Drug-Market-Forecast

    Wish to get a free scope of the report? Click here.

    What is Age-related Macular Degeneration Drug?

    Age-related macular degeneration (AMD) is a chronic health condition which results in central vision loss because of damage to the central area of the retina (macula). It can be categorized as dry age-related macular degeneration and wet age-related macular degeneration. 

    Key Players

    Key players operating in the global Age-Related Macular Degeneration Drug market are-

    • Bayer AG (Germany),
    • F. Hoffmann-La Roche AG (Switzerland),
    • Regeneron Pharmaceuticals, Inc. (The U.S),
    • Novartis International AG (Switzerland),
    • Bausch Health Companies Inc. (Canada),
    • Pfizer Inc. (The U.S),
    • Kubota Pharmaceutical (The U.S),
    • Ophthotech Corporation (The U.S),
    • GlaxoSmithKline PLC (UK),
    • Rxi Pharmaceuticals, Inc. (The U.S),
    • Alimera Sciences Inc. (The U.S),
    • Santen Pharmaceuticals Co. (Japan), and
    • Allergan, Inc. (Ireland).

    Market Dynamics

    The growth of the global age-related macular degeneration drug market is primarily driven by rising incidences of eye-related health issues, particularly among adults.

    • The growing aging populace is another factor fuelling the product demand.
    • The increasing prevalence of chronic diseases such as obesity and high blood pressure can result in macular degeneration and thus, is likely to augment the market growth.
    • In addition to this, increasing demand for advanced age-related macular degeneration drugs is likely to create lucrative opportunities for the players operating in the global market in the coming years.

    Segments' Analysis

    Application Trends

    By application, the age-related macular degeneration drug market has been bifurcated into hospitals & clinics, diagnostic centres, and academic research institutes.

    • The hospital & clinics segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period.
    • The segment growth can be attributed to the presence of established infrastructure and skilled professional healthcare providers.

    Regional Trends

    By region, the market in North America accounted for the largest market share in 2020 and is projected to grow at a significant CAGR during the assessment period.

    • The regional growth can be attributed to expanding geriatric populace and presence of key market players such as Regeneron Pharmaceuticals, Inc. (The U.S), and Pfizer Inc. (The U.S).
    • The market in Asia-Pacific is expected to be driven by significant growth of the healthcare industry.

    COVID-19 Impact on Global Age Related Macular Degeneration Drug Market

    Covid-19 outbreak impacted the growth of the age-related macular degeneration drug market negatively. The spread of coronavirus led to the enforcement of lockdown to curb the spread of the virus. This led to travel restrictions and supply chain disruptions. In addition to this, patients postponed their appointments due to fear of infection and thus, affected the market growth.

    Critical Questions Answered in the Report

    • What are the key trends in the global Age Related Macular Degeneration Drug market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the global Age Related Macular Degeneration Drug market?
    • What are the key strategies adopted by the major vendors to lead in the global Age Related Macular Degeneration Drug market?
    • What is the market share of the top vendors?

    Get the full scope of the report. Register Here

    Target Audience

    Here is the list of the group of customers that the Age-related Macular Degeneration Drug market hopes to have the greatest opportunity to convert-

    • Age related macular degeneration drug distributors
    • Age related macular degeneration drug suppliers
    • Age related macular degeneration drug manufacturers
    • Logistics organizations
    • Government bodies

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].

    Frequently Asked Questions (FAQs)

    Bayer AG (Germany), F. Hoffmann-La Roche AG (Switzerland), Regeneron Pharmaceuticals, Inc. (The U.S), Novartis International AG (Switzerland), Bausch Health Companies Inc. (Canada), Pfizer Inc. (The U.S), Kubota Pharmaceutical (The U.S), Ophthotech Corporation (The U.S), GlaxoSmithKline PLC (UK), Rxi Pharmaceuticals, Inc. (The U.S), Alimera Sciences Inc. (The U.S), Santen Pharmaceuticals Co. (Japan) and Allergan, Inc. (Ireland) are among the key players in the age related macular degeneration drug market.

    North America accounted for the largest market share in 2020 and is projected to grow at a significant CAGR.

    The hospital & clinics segment is expected to witness significant growth rate in the age-related macular degeneration drug market in the coming years.

    Rising incidences of eye-related health issues, growing aging populace, increasing prevalence of chronic diseases are the factors driving the growth pf age-related macular degeneration drug market.

    Age related macular degeneration drug distributors, Age related macular degeneration drug suppliers, Age related macular degeneration drug manufacturers, Logistics organizations, Government bodies are the target audience in the age-related macular degeneration drug market.

    •